Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter Antibody
Advertisement
Glycotope GmbH announced the enrollment of the first patients in a phase I dose finding trial to evaluate safety and tolerability of TrasGEX™. TrasGEX™ is a biobetter of the marketed Trastuzumab / Herceptin™ targeting the HER2-receptor, commonly overexpressed in a variety of cancers. TrasGEX™ has been glycooptimized to yield a manifold higher anti-tumor activity and is supposed to be suitable for the treatment of an enlarged patient spectrum. It was developed using GlycoExpress™, the company's development and production platform based on glycoengineered human cell lines for biopharmaceuticals with fully human and optimized Glycosylation.
"We are delighted to see our 4th glycooptimized biopharmaceutical product in clinical trials", says Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope. "After CetuGEX™ and PankoMab-GEX™, TrasGEX is our 3rd anti-cancer antibody which entered clinical trials in time. GlycoExpress has been proven to be the broadest glycooptimization technology not only for antibodies but also for most other glycoproteins. Our glycooptimized Follicle-Stimulating Hormone FSH-GEX™ has already completed clinical phase Ia with very exciting results. Currently we are advancing a broad range of pre-clinical products in various therapeutic areas".
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors
'Jumping genes' create antibiotic resistance - 'Jumping genes' find gaps in DNA, cause widespread antibiotic resistance in bacteria, study finds
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform - Expansion of senior team to focus on drug discovery and development
INTEGRA Biosciences announced strong end of year sales of over Euro 5 million - Well positioned for growth in 2004
Major Plant Research Company Takes World-Wide License to Genomatix´ Regulatory Sequence Analysis Application
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
